(Q35642631)

9 August 2017

1 reference

title

Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents (English)

1 reference

9 August 2017

Yun Dai

1

1 reference

9 August 2017

Steven Grant

series ordinal

2

1 reference

9 August 2017

publication date

1 March 2004

1 reference

9 August 2017

published in

Current Oncology Reports

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

123-130

1 reference

Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Phase II study of flavopiridol in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Mechanisms of action of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Signal transduction--directed cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Structural basis for Chk1 inhibition by UCN-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-004-0024-3

The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

21 January 2018

1 reference

12 December 2020

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.

1 reference

12 December 2020

Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

1 reference

12 December 2020

An ATM-independent S-phase checkpoint response involves CHK1 pathway

1 reference

12 December 2020

Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

1 reference

12 December 2020

Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients

1 reference

12 December 2020

Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

1 reference

12 December 2020

Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.

1 reference

12 December 2020

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

12 December 2020

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells

1 reference

12 December 2020

Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells

1 reference

12 December 2020

Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).

1 reference

12 December 2020

Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.

1 reference

12 December 2020

UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.

1 reference

12 December 2020

The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells

1 reference

12 December 2020

Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase

1 reference

12 December 2020

Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

1 reference

12 December 2020

Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.

1 reference

12 December 2020

Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.

1 reference

12 December 2020

Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial

1 reference

12 December 2020

Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit

1 reference

12 December 2020

10.1007/S11912-004-0024-3

Identifiers

DOI

1 reference

9 August 2017

1 reference